Page last updated: 2024-12-07

n-(5-(2,3-dihydrobenzofuryl)sulfonyl)-n'-(3,4-dichlorophenyl)urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea: a second generation diarylsulfonylurea; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127737
CHEMBL ID307177
SCHEMBL ID30351
MeSH IDM0248678

Synonyms (15)

Synonym
ilx-295501
ly295501
CHEMBL307177
ly-295501
1-(3,4-dichlorophenyl)-3-(2,3-dihydro-1-benzofuran-5-ylsulfonyl)urea
240y4yo0tn ,
unii-240y4yo0tn
150869-74-2
5-benzofuransulfonamide, n-(((3,4-dichlorophenyl)amino)carbonyl)-2,3-dihydro-
n-(5-(2,3-dihydrobenzofuryl)sulfonyl)-n'-(3,4-dichlorophenyl)urea
n-(((3,4-dichlorophenyl)amino)carbonyl)-2,3-dihydro-5-benzofuransulfonamide
SCHEMBL30351
DTXSID20164633
DB12574
Q27253797

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Both drugs were more toxic to the tumorigenic cells than to the normal cells, but LY295501 was significantly more toxic to both cells."( Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines.
Berezesky, IK; Best, CJ; Boder, GB; Merriman, RL; Phelps, PC; Tanzer, LR; Trump, BF, 1995
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity."( A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Callaghan, JT; Diab, S; Forouzesh, B; Gazak, R; Goetz, A; Hammond, LA; Rowinsky, EK; Schwartz, G; Smetzer, L; Takimoto, CH; Von Hoff, DD, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Both types of assayed compounds, the N-(2-pyridylsulfonyl)urea and N-(2-pyridylsulfenyl)urea derivatives, inhibited by 50% the growth of the CCRF-CEM cell line at a dosage near to 1 microM."( Synthesis and cytotoxic activity of N-(2-pyridylsulfenyl)urea derivatives. A new class of potential antineoplastic agents.
Arteaga, C; Encío, I; Gil, MJ; González, A; Mañú, MA; Martínez-Merino, V; Migliaccio, M, 1999
)
0.3
" Because severe toxicities were being reported in other trials at doses that encompassed this range and a cumulative toxicity profile was emerging, the study was suspended and then reinitiated to further reevaluate the lower dosing range."( A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Callaghan, JT; Diab, S; Forouzesh, B; Gazak, R; Goetz, A; Hammond, LA; Rowinsky, EK; Schwartz, G; Smetzer, L; Takimoto, CH; Von Hoff, DD, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID24233Partition coefficient (logP)1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and cytotoxic activity of N-(2-pyridylsulfenyl)urea derivatives. A new class of potential antineoplastic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (81.82)18.2507
2000's2 (18.18)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.60 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews2 (18.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]